Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

被引：0
|
作者：
Hofmeister, Craig C.
Chari, Ajai
Cohen, Yael
Spencer, Andrew
Voorhees, Peter M.
Estell, Jane
Venner, Christopher P.
Sandhu, Irwindeep
Jenner, Matthew W.
Williams, Cathy
Cavo, Michele
Van de Donk, Niels W. C. J.
Beksac, Meral
Kuppens, Steven
Bandekar, Rajesh
Neff, Tobias
Heuck, Christoph
Qi, Ming
Goldschmidt, Hartmut
Landgren, Ola
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
510
引用
收藏
页数：3
相关论文
共 50 条
  • [41] MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma.
    Fonseca, Rafael
    Kuroda, Junya
    Ishida, Tadao
    Popat, Rakesh
    Huang, Jeffrey S. Y.
    Yver, Anne
    Vandendries, Erik
    Elmeliegy, Mohamed
    Ma, Wei Dong
    Sborov, Douglas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    Lokhorst, Henk M.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Liu, Kevin
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [43] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
    Chari, Ajai
    Nahi, Hareth
    Mateos, Maria-Victoria
    Lokhorst, Henk M.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Liu, Kevin
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    BLOOD, 2017, 130
  • [44] Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
    Sonneveld, Pieter
    Chanan-Khan, Asher
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania
    Munder, Markus
    Mateos, Maria-Victoria
    Mark, Tomer M.
    Levin, Mark-David
    Ahmadi, Tahamtan
    Qin, Xiang
    Mayo, Wendy Garvin
    Gai, Xue
    Carey, Jodi
    Carson, Robin
    Spencer, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1600 - +
  • [45] Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
    Dimopoulos, Meletios A.
    Oriol, Albert
    Nahi, Hareth
    San-Miguel, Jesus
    Bahlis, Nizar J.
    Usmani, Saad Z.
    Rabin, Neil
    Orlowski, Robert Z.
    Suzuki, Kenshi
    Plesner, Torben
    Yoon, Sung-Soo
    Ben Yehuda, Dina
    Richardson, Paul G.
    Goldschmidt, Hartmut
    Reece, Donna
    Ahmadi, Tahamtan
    Qin, Xiang
    Mayo, Wendy Garvin
    Gai, Xue
    Carey, Jodi
    Carson, Robin
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1590 - +
  • [46] Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
    Chari, Ajai
    Lonial, Sagar
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Ifthikharuddin, Jainulabdeen J.
    Qin, Xiang
    Masterson, Tara
    Nottage, Kerri
    Schecter, Jordan M.
    Ahmadi, Tahamtan
    Weiss, Brendan
    Krishnan, Amrita
    Lentzsch, Suzanne
    BLOOD, 2015, 126 (23)
  • [47] Interim Results of a Phase 2 Trial of Isatuximab-Lenalidomide for Patients with High-Risk Smoldering Multiple Myeloma
    Thomas, Sheeba
    Manasanch, Elisabet
    Korde, Neha
    Lee, Hans
    Jagannath, Sundar
    Becnel, Melody
    Kaufman, Gregory
    Patel, Krina
    Iyer, Swaminathan
    Mailankody, Sham
    Weber, Donna
    Lutter-Berka, Zuzana
    Carpenter, Shawnee
    Nolasco, David Berrios
    Hildebrandt, Michelle
    Feng, Lei
    Amini, Behrang
    Neelapu, Sattva
    Orlowski, Robert
    Landgren, Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S27 - S27
  • [48] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Shinsuke Iida
    Tohru Izumi
    Takuya Komeno
    Yasuhito Terui
    Takaaki Chou
    Takashi Ikeda
    Deborah Berg
    Shinichi Fukunaga
    Kenkichi Sugiura
    Makoto Sasaki
    International Journal of Clinical Oncology, 2022, 27 : 224 - 233
  • [49] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
    Grammatico, Sara
    Bringhen, Sara
    Vozella, Federico
    Siniscalchi, Agostina
    Boccadoro, Mario
    Petrucci, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
  • [50] A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma
    Iida, Shinsuke
    Izumi, Tohru
    Komeno, Takuya
    Terui, Yasuhito
    Chou, Takaaki
    Ikeda, Takashi
    Berg, Deborah
    Fukunaga, Shinichi
    Sugiura, Kenkichi
    Sasaki, Makoto
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 224 - 233
12345